Mathew S Maurer

List of Publications by Year
in descending order

309 papers	22,886 citations	13865 67 h-index	9861 141 g-index
316 all docs	316 docs citations	316 times ranked	19195 citing authors

#	Article	IF	Citations
1	Extrapulmonary manifestations of COVID-19. Nature Medicine, 2020, 26, 1017-1032.	30.7	2,300
2	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine, 2018, 379, 1007-1016.	27.0	1,558
3	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 2016, 133, 2404-2412.	1.6	1,335
4	Frailty Assessment in the Cardiovascular Care of Older Adults. Journal of the American College of Cardiology, 2014, 63, 747-762.	2.8	850
5	Transthyretin Amyloid Cardiomyopathy. Journal of the American College of Cardiology, 2019, 73, 2872-2891.	2.8	573
6	^{99m} Tc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses. Circulation: Cardiovascular Imaging, 2013, 6, 195-201.	2.6	499
7	Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. European Heart Journal, 2017, 38, 2879-2887.	2.2	489
8	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2020, 396, 759-769.	13.7	481
9	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2021, 42, 1554-1568.	2.2	434
10	The Impact of Frailty Status on Survival After Transcatheter Aortic Valve Replacement in Older Adults With Severe Aortic Stenosis. JACC: Cardiovascular Interventions, 2012, 5, 974-981.	2.9	411
11	Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. Journal of the American College of Cardiology, 2016, 68, 161-172.	2.8	338
12	Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation, 2020, 142, e7-e22.	1.6	338
13	Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation, 2017, 135, 1357-1377.	1.6	319
14	Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation, 2019, 139, 431-443.	1.6	319
15	Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circulation: Heart Failure, 2019, 12, e006075.	3.9	312
16	Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging. JAMA Cardiology, 2016, 1, 880.	6.1	304
17	THAOS â€“ The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Current Medical Research and Opinion, 2013, 29, 63-76.	1.9	246
18	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€”evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2019, 26, 2065-2123.	2.1	230

#	Article	IF	Citations
19	Heart Failure With a Normal Ejection Fraction. Circulation, 2003, 107, 656-658.	1.6	226
20	Single-beat estimation of end-diastolic pressure-volume relationship: a novel method with potential for noninvasive application. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H403-H412.	3.2	223
21	Multimorbidity in Older Adults With Cardiovascular Disease. Journal of the American College of Cardiology, 2018, 71, 2149-2161.	2.8	216
22	Review and Analysis of Existing Mobile Phone Apps to Support Heart Failure Symptom Monitoring and Self-Care Management Using the Mobile Application Rating Scale (MARS). JMIR MHealth and UHealth, 2016, 4, e74.	3.7	212
23	Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS). American Heart Journal, 2012, 164, 222-228.e1.	2.7	209
24	Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. European Heart Journal, 2008, 29, 741-747.	2.2	203
25	Cardiac Care for Older Adults. Journal of the American College of Cardiology, 2011, 57, 1801-1810.	2.8	187
26	Diastolic dysfunction. Journal of the American College of Cardiology, 2004, 44, 1543-1549.	2.8	185
27	Left Heart Failure With a Normal Ejection Fraction: Identification of Different Pathophysiologic Mechanisms. Journal of Cardiac Failure, 2005, 11, 177-187.	1.7	184
28	Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Failure Reviews, 2015, 20, 163-178.	3.9	178
29	Transthyretin Stabilization by AG10 in Symptomatic Transthyretin AmyloidÂCardiomyopathy. Journal of the American College of Cardiology, 2019, 74, 285-295.	2.8	170
30	Ventricular Structure and Function in Hypertensive Participants With Heart Failure and a Normal Ejection Fraction. Journal of the American College of Cardiology, 2007, 49, 972-981.	2.8	166
31	Secondary Prevention of Atherosclerotic Cardiovascular Disease in Older Adults. Circulation, 2013, 128, 2422-2446.	1.6	166
32	Reduced Handgrip Strength as a Marker of Frailty Predicts Clinical Outcomes in Patients With Heart Failure Undergoing Ventricular Assist Device Placement. Journal of Cardiac Failure, 2014, 20, 310-315.	1.7	155
33	Prevalence and Prognostic Significance of Low QRS Voltage Among the Three Main Types of Cardiac Amyloidosis. American Journal of Cardiology, 2014, 114, 1089-1093.	1.6	154
34	Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp>orking <scp>G</scp>roup on <scp>M</scp>yocardial and <scp>P</scp>ericardial <scp>D</scp>iseases. European Journal of Heart Failure, 2021, 23, 512-526.	7.1	153
35	International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation, 2018, 137, 1015-1023.	1.6	149
36	Cardiac amyloidosis: the great pretender. Heart Failure Reviews, 2015, 20, 117-124.	3.9	147

#	Article	IF	Citations
37	Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation, 2020, 141, 1214-1224.	1.6	147
38	Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood, 2020, 136, 71-80.	1.4	146
39	Rationale and design of the Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure (TAVR UNLOAD) trial. American Heart Journal, 2016, 182, 80-88.	2.7	142
40	Knowledge Gaps in Cardiovascular Care of the Older Adult Population. Circulation, 2016, 133, 2103-2122.	1.6	139
41	Arterial Stiffness in Mild Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3326-3330.	3.6	132
42	Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis. Journal of the American College of Cardiology, 2020, 75, 2851-2862.	2.8	131
43	Deprescribing in Older Adults With Cardiovascular Disease. Journal of the American College of Cardiology, 2019, 73, 2584-2595.	2.8	126
44	Development of Heart Failure in Chronic Hypertensive Dahl Rats. Hypertension, 2006, 47, 901-911.	2.7	125
45	Diflunisal for ATTR Cardiac Amyloidosis. Congestive Heart Failure, 2012, 18, 315-319.	2.0	124
46	Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurology and Therapy, 2016, 5, 1-25.	3.2	124
47	Effects of an Interatrial Shunt on Rest and Exercise Hemodynamics: Results of a Computer Simulation in Heart Failure. Journal of Cardiac Failure, 2014, 20, 212-221.	1.7	111
48	Tafamidis in Transthyretin Amyloid Cardiomyopathy. Circulation: Heart Failure, 2015, 8, 519-526.	3.9	110
49	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2019, 25, e1-e39.	1.7	107
50	Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). European Heart Journal, 2022, 43, 391-400.	2.2	105
51	What to Expect From the Evolving Field ofÂGeriatric Cardiology. Journal of the American College of Cardiology, 2015, 66, 1286-1299.	2.8	102
52	Polypharmacy in Older Adults Hospitalized for Heart Failure. Circulation: Heart Failure, 2020, 13, e006977.	3.9	102
53	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2â€"Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology, 2020, 27, 659-673.	2.1	97
54	Usefulness of Two-Dimensional Echocardiographic Parameters of the Left Side of the Heart to Predict Right Ventricular Failure After Left Ventricular Assist Device Implantation. American Journal of Cardiology, 2012, 109, 246-251.	1.6	96

#	Article	IF	Citations
55	Perioperative Outcome and Longâ€Term Mortality for Heart Failure Patients Undergoing Intermediateâ€• and Highâ€Risk Noncardiac Surgery: Impact of Left Ventricular Ejection Fraction. Congestive Heart Failure, 2010, 16, 45-49.	2.0	95
56	Nuclear imaging modalities for cardiac amyloidosis. Journal of Nuclear Cardiology, 2014, 21, 175-184.	2.1	93
57	Characterization of the <scp>inflammatoryâ€•metabolic</scp> phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. European Journal of Heart Failure, 2020, 22, 1551-1567.	7.1	93
58	Heart Failure with Preserved Ejection Fraction: Persistent Diagnosis, Therapeutic Enigma. Current Cardiovascular Risk Reports, 2011, 5, 440-449.	2.0	89
59	Metaâ€Analysis Global Group in Chronic (MAGGIC) Heart Failure Risk Score: Validation of a Simple Tool for the Prediction of Morbidity and Mortality in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2018, 7, e009594.	3.7	87
60	Pressure-Volume Relationships in Patients With Transthyretin (ATTR) Cardiac Amyloidosis Secondary to V122I Mutations and Wild-Type Transthyretin. Circulation: Heart Failure, 2011, 4, 121-128.	3.9	84
61	Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis. Journal of Nuclear Cardiology, 2016, 23, 1355-1363.	2.1	83
62	Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable. Annual Review of Medicine, 2020, 71, 203-219.	12.2	82
63	Home-Delivered Meals Postdischarge From Heart Failure Hospitalization. Circulation: Heart Failure, 2018, 11, e004886.	3.9	81
64	TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis. Circulation: Heart Failure, 2018, 11, e004769.	3.9	78
65	Association of Carpal Tunnel Syndrome With Amyloidosis, HeartÂFailure, and Adverse Cardiovascular Outcomes. Journal of the American College of Cardiology, 2019, 74, 15-23.	2.8	77
66	Myocardial contraction fraction: a volumetric index of myocardial shortening by freehand three-dimensional echocardiography. Journal of the American College of Cardiology, 2002, 40, 325-329.	2.8	73
67	Cardiac Transplantation Using Extended-Donor Criteria Organs for Systemic Amyloidosis Complicated by Heart Failure. Transplantation, 2007, 83, 539-545.	1.0	73
68	The feasibility of measuring frailty to predict disability and mortality in older medical intensive care unit survivors. Journal of Critical Care, 2014, 29, 401-408.	2.2	73
69	Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis. European Journal of Heart Failure, 2021, 23, 250-258.	7.1	71
70	Relation Between Six-Minute Walk Test Performance and Outcomes After Transcatheter Aortic Valve Implantation (from the PARTNER Trial). American Journal of Cardiology, 2013, 112, 700-706.	1.6	70
71	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Journal of Cardiac Failure, 2019, 25, 854-865.	1.7	70
72	Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF). Journal of Cardiac Failure, 2015, 21, 479-488.	1.7	69

#	Article	IF	Citations
73	The myocardial contraction fraction is superior to ejection fraction in predicting survival in patients with AL cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 61-66.	3.0	69
74	Comparison of Ventricular Structure and Function in Chinese Patients With Heart Failure and Ejection Fractions >55% Versus 40% to 55% Versus <40%. American Journal of Cardiology, 2009, 103, 845-851.	1.6	67
75	Left Atrial Decompression Pump forÂSevere Heart Failure With PreservedÂEjection Fraction. JACC: Heart Failure, 2015, 3, 275-282.	4.1	67
76	Comparison of Blood Volume Characteristics in Anemic Patients With Low Versus Preserved Left Ventricular Ejection Fractions. American Journal of Cardiology, 2008, 102, 1069-1072.	1.6	66
77	Gerotechnology for Older Adults With Cardiovascular Diseases. Journal of the American College of Cardiology, 2020, 76, 2650-2670.	2.8	66
78	Transthyretin Cardiac Amyloidoses in Older North Americans. Journal of the American Geriatrics Society, 2012, 60, 765-774.	2.6	64
79	Mechanisms Underlying Improvements in Ejection Fraction With Carvedilol in Heart Failure. Circulation: Heart Failure, 2009, 2, 189-196.	3.9	63
80	Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart, 2016, 3, e000289.	2.3	62
81	Joint Commission Requirements for Discharge Instructions in Patients With Heart Failure: Is Understanding Important for Preventing Readmissions?. Journal of Cardiac Failure, 2014, 20, 641-649.	1.7	61
82	Gait Speed and Dependence in Activities of Daily Living in Older Adults With Severe Aortic Stenosis. Clinical Cardiology, 2012, 35, 307-314.	1.8	60
83	Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Family Practice, 2020, 21, 198.	2.9	60
84	Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy) Tj ETQq0 0 0 rgBT /Overlock 10	3.9	59
85	Prevalence and prognostic significance of exercise-induced supraventricular tachycardia in apparently healthy volunteers. American Journal of Cardiology, 1995, 75, 788-792.	1.6	58
86	Noninvasive Identification of ATTRwt Cardiac Amyloid: The Re-emergence of Nuclear Cardiology. American Journal of Medicine, 2015, 128, 1275-1280.	1.5	58
87	Can a Left Ventricular Assist Device in Individuals with Advanced Systolic Heart Failure Improve or Reverse Frailty?. Journal of the American Geriatrics Society, 2017, 65, 2383-2390.	2.6	58
88	Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center. Aging Health, 2013, 9, 229-235.	0.3	57
89	Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis. Journal of Cardiac Failure, 2020, 26, 753-759.	1.7	57
90	Cardiac Transplantation in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2012, 110, 568-574.	1.6	56

#	Article	IF	Citations
91	A Prognostic Model for 6-Month Mortality in Elderly Survivors of Critical Illness. Chest, 2013, 143, 910-919.	0.8	56
92	Knowledge Gaps in Cardiovascular Care of Older Adults: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society: Executive Summary. Journal of the American Geriatrics Society, 2016, 64, 2185-2192.	2.6	56
93	Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier?. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 224-228.	3.0	56
94	ATTR Amyloidosis: Current and Emerging Management Strategies. JACC: CardioOncology, 2021, 3, 488-505.	4.0	56
95	Upright Posture and Postprandial Hypotension in Elderly Persons. Annals of Internal Medicine, 2000, 133, 533.	3.9	55
96	Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 58-59.	3.0	55
97	Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovascular Drugs and Therapy, 2020, 34, 357-370.	2.6	55
98	Transthyretin Cardiac Amyloidosis in Black Americans. Circulation: Heart Failure, 2016, 9, e002558.	3.9	54
99	Transthyretin Cardiac Amyloidosis in Older Americans. Journal of Cardiac Failure, 2016, 22, 996-1003.	1.7	53
100	Amyloidosis cardiomyopathy. Current Opinion in Cardiology, 2018, 33, 571-579.	1.8	53
101	Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate. JACC: Cardiovascular Imaging, 2021, 14, 1221-1231.	5.3	52
102	Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy. JACC: Heart Failure, 2021, 9, 115-123.	4.1	52
103	Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis. Circulation Research, 2021, 128, 1554-1575.	4.5	52
104	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure. Circulation: Heart Failure, 2016, 9, .	3.9	51
105	Myocardial Contraction Fraction by M-Mode Echocardiography Is Superior to Ejection Fraction in Predicting Mortality in Transthyretin Amyloidosis. Journal of Cardiac Failure, 2018, 24, 504-511.	1.7	51
106	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. Circulation: Cardiovascular Imaging, 2018, 11, e006588.	2.6	51
107	Mechanisms of heart failure with well preserved ejection fraction in dogs following limited coronary microembolization. Cardiovascular Research, 2004, 64, 72-83.	3.8	50
108	Self-Reported Lack of Energy (Anergia) Among Elders in a Multiethnic Community. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2008, 63, 707-714.	3.6	50

#	Article	IF	Citations
109	The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. Current Medical Research and Opinion, 2013, 29, 77-84.	1.9	50
110	Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis â€“ Report from the Transthyretin Amyloidosis Outcome Survey (THAOS). PLoS ONE, 2017, 12, e0173086.	2.5	50
111	Effects of age on outcome of tilt-table testing. American Journal of Cardiology, 1999, 83, 1055-1058.	1.6	48
112	Circulating Activated and Effector Memory T Cells Are Associated with Calcification and Clonal Expansions in Bicuspid and Tricuspid Valves of Calcific Aortic Stenosis. Journal of Immunology, 2011, 187, 1006-1014.	0.8	48
113	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€”Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging, 2021, 14, e000029.	2.6	48
114	Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood, 2021, 138, 2632-2641.	1.4	48
115	Treating Anemia in Older Adults With Heart Failure With a Preserved Ejection Fraction With Epoetin Alfa. Circulation: Heart Failure, 2013, 6, 254-263.	3.9	47
116	Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis. Journal of Nuclear Cardiology, 2018, 25, 181-190.	2.1	47
117	18Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis. Journal of Nuclear Cardiology, 2018, 25, 1559-1567.	2.1	46
118	Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients. Science Translational Medicine, 2017, 9, .	12.4	44
119	The Lymphocytic Infiltration in Calcific Aortic Stenosis Predominantly Consists of Clonally Expanded T Cells. Journal of Immunology, 2007, 178, 5329-5339.	0.8	37
120	Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis. JACC: CardioOncology, 2020, 2, 414-424.	4.0	37
121	The Effect of Body Mass Index on Complications from Cardiac Surgery in the Oldest Old. Journal of the American Geriatrics Society, 2002, 50, 988-994.	2.6	36
122	Sexâ€•and Raceâ€Related Differences in Characteristics and Outcomes of Hospitalizations for Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2017, 6, .	3.7	36
123	Critical Comparison of Documents FromÂScientific Societies on CardiacÂAmyloidosis. Journal of the American College of Cardiology, 2022, 79, 1288-1303.	2.8	35
124	Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 175-180.	3.0	34
125	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€”evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2021, 28, 1769-1774.	2.1	34
126	The Columbia Cooperative Aging Program: An Interdisciplinary and Interdepartmental Approach to Geriatric Education for Medical Interns. Journal of the American Geriatrics Society, 2006, 54, 520-526.	2.6	33

#	Article	IF	Citations
127	Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction. European Heart Journal, 2015, 36, 2595-2597.	2.2	33
128	Tafamidisâ€"A Pricey Therapy for a Not-So-Rare Condition. JAMA Cardiology, 2020, 5, 247.	6.1	33
129	The Frailty Phenotype and Palliative Care Needs of Older Survivors of Critical Illness. Journal of the American Geriatrics Society, 2017, 65, 1168-1175.	2.6	31
130	Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 30-34.	3.0	31
131	Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Failure Reviews, 2022, 27, 785-793.	3.9	31
132	The Prevalence and Impact of Anergia (Lack of Energy) in Subjects With Heart Failure and its Associations With Actigraphy. Journal of Cardiac Failure, 2009, 15, 145-151.	1.7	30
133	Gerontechnologies for Older Patients with Heart Failure: What is the Role of Smartphones, Tablets, and Remote Monitoring Devices in Improving Symptom Monitoring and Self-Care Management?. Current Cardiovascular Risk Reports, 2016, 10, 1.	2.0	30
134	How Should Physicians Assess Myocardial Contraction?. JACC: Cardiovascular Imaging, 2020, 13, 873-878.	5.3	30
135	Ventricular Pump Function in Heart Failure with Normal Ejection Fraction: Insights from Pressure-Volume Measurements. Progress in Cardiovascular Diseases, 2006, 49, 182-195.	3.1	28
136	Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology. PLoS ONE, 2015, 10, e0145816.	2.5	28
137	Cardiac dysfunction in Î²-carotene-15,15â€²-dioxygenase-deficient mice is associated with altered retinoid and lipid metabolism. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H1675-H1684.	3.2	27
138	Noncompressibility of myocardium during systole with freehand three-dimensional echocardiography. Journal of the American Society of Echocardiography, 2002, 15, 1503-1506.	2.8	26
139	Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging. Canadian Journal of Cardiology, 2016, 32, 1166.e1-1166.e10.	1.7	26
140	Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2021, 14, e007849.	3.9	26
141	Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis. JACC: Heart Failure, 2021, 9, 736-746.	4.1	26
142	Clinical Outcomes After Left Ventricular Assist Device Implantation in Older Adults. JACC: Heart Failure, 2019, 7, 1069-1078.	4.1	25
143	One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 115-116.	3.0	24
144	Association Between Functional Impairment and Medication Burden in Adults with Heart Failure. Journal of the American Geriatrics Society, 2019, 67, 284-291.	2.6	24

#	Article	IF	Citations
145	Systemic embolism in amyloid transthyretin cardiomyopathy. European Journal of Heart Failure, 2022, 24, 1387-1396.	7.1	23
146	Ventricular Volume and Length in Hypertensive Diastolic Heart Failure. Journal of the American Society of Echocardiography, 2005, 18, 1051-1057.	2.8	22
147	Mechanical Circulatory Support Device Utilization and Heart Transplant Waitlist Outcomes in Patients With Restrictive and Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2018, 11, e004665.	3.9	22
148	Remote Cardiac Monitoring in Patients With Heart Failure. JAMA Cardiology, 2022, 7, 556.	6.1	22
149	Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update. Orphanet Journal of Rare Diseases, 2022, 17, .	2.7	22
150	Myocardial Contraction Fraction. Journal of the American College of Cardiology, 2018, 71, 255-256.	2.8	21
151	Tafamidis for Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine, 2019, 380, 196-197.	27.0	21
152	Prescribing Patterns of HeartÂFailure-Exacerbating Medications Following a Heart Failure Hospitalization. JACC: Heart Failure, 2020, 8, 25-34.	4.1	21
153	Peripheral neuropathy symptoms in wild type transthyretin amyloidosis. Journal of the Peripheral Nervous System, 2020, 25, 265-272.	3.1	21
154	Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). American Journal of Cardiology, 2021, 141, 98-105.	1.6	21
155	Improved Cardiovascular Disease Outcomes in Older Adults. F1000Research, 2016, 5, 112.	1.6	21
156	Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. JACC: CardioOncology, 2021, 3, 537-546.	4.0	21
157	Older Adults Can Successfully Monitor Symptoms Using an Inclusively Designed Mobile Application. Journal of the American Geriatrics Society, 2020, 68, 1313-1318.	2.6	20
158	Sex Differences in the Phenotype of Transthyretin Cardiac Amyloidosis Due to Val122Ile Mutation: Insights from Noninvasive Pressureâ€“Volume Analysis. Journal of Cardiac Failure, 2021, 27, 67-74.	1.7	20
159	Two Decades of Cardiac Amyloidosis. JACC: CardioOncology, 2021, 3, 522-533.	4.0	20
160	Myocardial Contraction Fraction Predicts Cardiovascular Events in Patients With Hypertrophic Cardiomyopathy and Normal Ejection Fraction. Journal of Cardiac Failure, 2019, 25, 450-456.	1.7	19
161	Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis. Journal of the American Heart Association, 2021, 10, e022859.	3.7	19
162	Association of Transthyretin Val122Ile Variant With Incident Heart Failure Among Black Individuals. JAMA - Journal of the American Medical Association, 2022, 327, 1368.	7.4	19

#	Article	IF	Citations
163	Relation of the Myocardial Contraction Fraction, as Calculated from M-Mode Echocardiography, With Incident Heart Failure, Atherosclerotic Cardiovascular Disease and Mortality (Results from the) Tj ETQq1 1 0.784314 rgBT /Overlo	2.6	17
164	Results of Phase I Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis. Blood, 2015, 126, 188-188.	1.4	18
165	Application of Proteomics Profiling for Biomarker Discovery in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research, 2019, 12, 569-579.	2.4	17
166	Markers of nutritional status and inflammation in transthyretin cardiac amyloidosis: association with outcomes and the clinical phenotype. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 73-80.	3.0	17
167	Transition of a Large Tertiary Heart Failure Program in Response to the COVID-19 Pandemic. Circulation: Heart Failure, 2020, 13, e007516.	3.9	17
168	DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 223-230.	3.0	17
169	Association between reduced myocardial contraction fraction and cardiovascular disease outcomes: The Multi-Ethnic Study of Atherosclerosis. International Journal of Cardiology, 2019, 293, 10-16.	1.7	16
170	Difference in Metabolomic Response to Exercise between Patients with and without Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research, 2021, 14, 246-255.	2.4	16
171	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Circulation: Cardiovascular Imaging, 2021, 14, e000030.	2.6	16
172	The Degree and Timing of Orthostatic Blood Pressure Changes in Relation to Falls in Nursing Home Residents. Journal of the American Medical Directors Association, 2004, 5, 233-238.	2.5	16
173	Technetium pyrophosphate myocardial uptake and peripheral neuropathy in a rare variant of familial transthyretin (TTR) amyloidosis (Ser23Asn): a case report and literature review. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 41-46.	3.0	15
174	Evaluating the safety and efficacy of sodium-restricted/Dietary Approaches to Stop Hypertension diet after acute decompensated heart failure hospitalization: Design and rationale for the Geriatric OUt of hospital Randomized MEal Trial in Heart Failure (GOURMET-HF). American Heart Journal, 2015, 169, 342-348.e4.	2.7	15
175	Outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis. Clinical Transplantation, 2020, 34, e14028.	1.6	15
176	The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types. Blood Reviews, 2021, 45, 100720.	5.7	15
177	Durable Mechanical Circulatory Support in Patients With Amyloid Cardiomyopathy. Circulation: Heart Failure, 2020, 13, e007931.	3.9	15
178	Dietary Interventions for Heart Failure in Older Adults: Re-Emergence of the Hedonic Shift. Progress in Cardiovascular Diseases, 2014, 57, 160-167.	3.1	14
179	Individual and Joint Effects of Pulse Pressure and Blood Pressure Treatment Intensity on Serious Adverse Events in the SPRINT Trial. American Journal of Medicine, 2018, 131, 1220-1227.e1.	1.5	14
180	Indications for Î²â€Blocker Prescriptions in Heart Failure with Preserved Ejection Fraction. Journal of the American Geriatrics Society, 2019, 67, 1461-1466.	2.6	14

#	Article	IF	Citations
181	99mTechnetium pyrophosphate scintigraphy with cadmium zinc telluride cameras is a highly sensitive and specific imaging modality to diagnose transthyretin cardiac amyloidosis. Journal of Nuclear Cardiology, 2020, 27, 371-380.	2.1	14
182	Comparing outcomes for infiltrative and restrictive cardiomyopathies under the new heart transplant allocation system. Clinical Transplantation, 2020, 34, e14109.	1.6	14
183	Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction. Trends in Cardiovascular Medicine, 2021, 31, 59-66.	4.9	14
184	Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Neurology and Therapy, 2021, 10, 753-766.	3.2	14
185	Prefrailty, impairment in physical function, and risk of incident heart failure among older adults. Journal of the American Geriatrics Society, 2021, 69, 2486-2497.	2.6	14
186	Heart failure in older adults: embracing complexity. Journal of Geriatric Cardiology, 2016, 13, 8-14.	0.2	14
187	Clinico-histopathologic and single-nuclei RNA-sequencing insights into cardiac injury and microthrombi in critical COVID-19. JCI Insight, 2022, 7, .	5.0	14
188	Left Ventricular Assist Device Therapy in Older Adults: Addressing Common Clinical Questions. Journal of the American Geriatrics Society, 2019, 67, 2410-2419.	2.6	13
189	Cardiac Amyloidosis A Rare Disease in Older Adults Hospitalized for Heart Failure?. Circulation: Heart Failure, 2019, 12, e006169.	3.9	13
190	False Positive 99mTc-Pyrophosphate Scanning Leading to Inappropriate Tafamidis Prescriptions. JACC: Cardiovascular Imaging, 2021, 14, 2042-2044.	5.3	13
191	HFpEF. Journal of the American College of Cardiology, 2014, 64, 550-552.	2.8	12
192	Perspectives on Implementing a Multidomain Approach to Caring for Older Adults With Heart Failure. Journal of the American Geriatrics Society, 2019, 67, 2593-2599.	2.6	12
193	Predicting the development of adverse cardiac events in patients with hypertrophic cardiomyopathy using machine learning. International Journal of Cardiology, 2021, 327, 117-124.	1.7	12
194	Improvement in Global Longitudinal Strain (GLS) Correlates with NT-Probnp Response in Patients with Cardiac Amyloidosis Treated on a Phase 1b Study of Anti-Amyloid Mab Cael-101. Blood, 2018, 132, 958-958.	1.4	12
195	Atrial fibrillation and falls in the elderly. Clinics in Geriatric Medicine, 2002, 18, 323-337.	2.6	11
196	Dissociation between exercise hemodynamics and exercise capacity in patients with chronic heart failure and marked increase in ejection fraction after treatment with beta-adrenergic receptor antagonists. American Journal of Cardiology, 2003, 91, 356-360.	1.6	11
197	Multiple Chronic Conditions and Heart Failure. JACC: Heart Failure, 2015, 3, 551-553.	4.1	11
198	Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Left Ventricular Assist Devices. Journal of Palliative Medicine, 2019, 22, 437-441.	1.1	11

#	Article	IF	Citations
199	ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. Orphanet Journal of Rare Diseases, 2021, 16, 204.	2.7	11
200	Relationship Between Accelerometer-Measured Activity and Self-Reported or Performance-Based Function in Older Adults with Severe Aortic Stenosis. Current Geriatrics Reports, 2015, 4, 377-384.	1.1	10
201	Deep Learning Analysis of Echocardiographic Images to Predict Positive Genotype in Patients With Hypertrophic Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2021, 8, 669860.	2.4	10
202	Syncope in older adults. Journal of Geriatric Cardiology, 2016, 13, 380-6.	0.2	10
203	Palliative Care Throughout the Journey of Life With a Left Ventricular Assist Device. Circulation: Heart Failure, 2016, 9, .	3.9	9
204	Contextualizing Myocardial Infarction: Comorbidities and Priorities in Older Adults. American Journal of Medicine, 2017, 130, 1144-1147.	1.5	9
205	The Truth Is Unfolding About Transthyretin Cardiac Amyloidosis. Circulation, 2019, 140, 27-30.	1.6	9
206	The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis. Orphanet Journal of Rare Diseases, 2020, 15, 268.	2.7	9
207	Untangling the physiology of transthyretin cardiac amyloidosis by leveraging echocardiographically derived pressureâ€“volume indices. European Heart Journal, 2020, 41, 1448-1450.	2.2	9
208	Impaired systemic venous capacitance: the neglected mechanism in patients with heart failure and a preserved ejection fraction?. European Journal of Heart Failure, 2020, 22, 173-176.	7.1	9
209	Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies. Journal of Heart and Lung Transplantation, 2022, 41, 199-207.	0.6	9
210	Facilitated Peer Mentorship to Support Aging Research: A REâ€AIM Evaluation of the CoMPAdRE Program. Journal of the American Geriatrics Society, 2019, 67, 804-810.	2.6	8
211	Demyelinating Neuropathy in a Patient Treated With Revusiran for Transthyretin (Thr60Ala) Amyloidosis. Journal of Clinical Neuromuscular Disease, 2019, 20, 120-128.	0.7	8
212	Prediction of Genotype Positivity in Patients With Hypertrophic Cardiomyopathy Using Machine Learning. Circulation Genomic and Precision Medicine, 2021, 14, e003259.	3.6	8
213	Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS. Cardiology and Therapy, 2021, 10, 481-490.	2.6	8
214	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2022, 28, e1-e4.	1.7	8
215	Gene Editing â€" A Cure for Transthyretin Amyloidosis?. New England Journal of Medicine, 2021, 385, 558-559.	27.0	8
216	Cardiac Scintigraphy and Screening for Transthyretin Cardiac Amyloidosis. Circulation, 2021, 144, 1005-1007.	1.6	8

#	Article	IF	Citations
217	Racial Differences in Val122Ile-Associated Transthyretin Cardiac Amyloidosis. Journal of Cardiac Failure, 2022, 28, 950-959.	1.7	8
218	Hypertrophic cardiomyopathy: New approaches and a time to reappraise older approaches. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 983-988.	0.8	7
219	Salt Taste Recognition in a Heart Failure Cohort. Journal of Cardiac Failure, 2017, 23, 538-544.	1.7	7
220	More Than Meets the Eye: Time for a New Imaging Paradigm to Test for Cardiac Amyloidosis. Journal of Cardiac Failure, 2018, 24, 87-89.	1.7	7
221	Early Diagnosis of Cardiac Amyloidosis by Carpal Tunnel Surgery. Journal of the American College of Cardiology, 2018, 72, 2051-2053.	2.8	7
222	Estimating cancer risk from 99mTc pyrophosphate imaging for transthyretin cardiac amyloidosis. Journal of Nuclear Cardiology, 2020, 27, 215-224.	2.1	7
223	Cardiovascular effects of hemoglobin response in patients receiving epoetin alfa and oral iron in heart failure with a preserved ejection fraction. Journal of Geriatric Cardiology, 2014, 11, 100-5.	0.2	7
224	Prescriptions for Potentially Inappropriate Medications from the Beers Criteria Among Older Adults Hospitalized for Heart Failure. Journal of Cardiac Failure, 2022, 28, 906-915.	1.7	7
225	Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 175-183.	3.0	7
226	Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Cardiology and Therapy, 2022, 11, 393-405.	2.6	7
227	Reply. Journal of the American College of Cardiology, 2017, 69, 758-759.	2.8	6
228	Association of Midlife Cardiovascular Risk Factors With the Risk of Heart Failure Subtypes Later in Life. Journal of Cardiac Failure, 2021, 27, 435-444.	1.7	6
229	Frailty subtypes and recovery in older survivors of acute respiratory failure: a pilot study. Thorax, 2021, 76, 350-359.	5.6	6
230	Cardiopulmonary exercise testing in patients with Cardiac Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 545-548.	0.4	6
231	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). Blood, 2015, 126, 1774-1774.	1.4	6
232	Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121009038.	3.9	6
233	Prevalence and Characteristics of Anergia (Lack of Energy) in Patients With Acute Coronary Syndrome. American Journal of Cardiology, 2012, 110, 1213-1218.	1.6	5
234	Couples Living With Cardiovascular Disease: Effects on the Marital Relationship. Journal of Family Social Work, 2014, 17, 21-36.	0.2	5

#	Article	IF	Citations
235	Transthyretin Cardiac Amyloidosis in Older Adults: Optimizing Cardiac Imaging to the Corresponding Diagnostic and Management Goal. Current Cardiovascular Risk Reports, 2017, 11, 1.	2.0	5
236	The Tafamidis Drug Development Program. JACC Basic To Translational Science, 2018, 3, 871-873.	4.1	5
237	Amyloidosis of the Brain and Heart. JACC: Heart Failure, 2019, 7, 129-131.	4.1	5
238	Trends and causes of hospitalizations in patients with amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 177-178.	3.0	5
239	The quintessential form of diastolic heart failure in older adults: Wild type transthyretin cardiac amyloidosis. Clinical Cardiology, 2020, 43, 171-178.	1.8	5
240	Systemic Amyloidosis due to Monoclonal Immunoglobulins. Hematology/Oncology Clinics of North America, 2020, 34, 1055-1068.	2.2	5
241	Cognition predicts days-alive-out-of-hospital after LVAD implantation. International Journal of Artificial Organs, 2021, 44, 952-955.	1.4	5
242	Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda. Blood, 2020, 136, 44-45.	1.4	5
243	Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda.. Journal of Clinical Oncology, 2018, 36, 8011-8011.	1.6	5
244	Cardiovascular Diseases That Have Emerged From the Darkness. Journal of the American Heart Association, 2021, 10, e021095.	3.7	5
245	Prognosticating in Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2019, 12, 834-836.	5.3	4
246	Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, , 1-2.	3.0	4
247	Too Stiff But Still Got Rhythm. JACC: Cardiovascular Imaging, 2022, 15, 30-32.	5.3	4
248	Proteomics profiling reveals a distinct high-risk molecular subtype of hypertrophic cardiomyopathy. Heart, 2022, 108, 1807-1814.	2.9	4
249	Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement. Journal of Nuclear Cardiology, 2022, 29, 2748-2760.	2.1	4
250	Multimorbidity is strongly associated with long-term but not short-term mortality after cardiac valve replacement. International Journal of Cardiology, 2016, 215, 417-421.	1.7	3
251	Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 165-166.	3.0	3
252	Frailty and Advanced Heart Failure in Older Adults. Current Cardiovascular Risk Reports, 2017, 11, 1.	2.0	3

#	Article	IF	Citations
253	Chronotropic incompetence and autonomic dysfunction as mechanisms of dyspnoea in patients with late stage cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 134-135.	3.0	3
254	Cost-effectiveness of technetium pyrophosphate scintigraphy versus heart biopsy for the diagnosis of transthyretin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 71-72.	3.0	3
255	Anticoagulation with Warfarin versus Novel Oral Anticoagulants in Atrial Fibrillation in Amyloid Transthyretin Amyloidosis Cardiomyopathy: A Retrospective Cohort Study. Journal of Cardiac Failure, 2019, 25, S82.	1.7	3
256	Initial Monthly Cost of Tafamidisâ€"the Real Price for Patientsâ€"Reply. JAMA Cardiology, 2020, 5, 848.	6.1	3
257	Recognition and Implications of Undiagnosed Cardiac Amyloid Patients in HFpEF Trials. JACC: Heart Failure, 2021, 9, 803-806.	4.1	3
258	A Decision-Making Framework for Objective Risk Assessment in Older Adults with Severe Symptomatic Aortic Stenosis. Current Geriatrics Reports, 2015, 4, 338-346.	1.1	2
259	Technetium 99m pyrophosphate radioisotope for diagnosis and prognosis of transthyretin cardiac amyloidosis: A call for collaboration. Journal of Nuclear Cardiology, 2018, 25, 1257-1259.	2.1	2
260	Beyond the Valve and into the Muscle: A Review of Coexisting Aortic Stenosis and Transthyretin Cardiac Amyloidosis. Structural Heart, 2019, 3, 462-468.	0.6	2
261	The importance of SPECT cardiac reconstruction for accurate 99mTc-pyrophosphate interpretation in TTR amyloidosis. Journal of Nuclear Cardiology, 2022, 29, 1478-1480.	2.1	2
262	Early-Onset of Transthyretin Amyloidosis in a Young Afro-Caribbean Woman With Thr60Ala Mutation. JACC: Case Reports, 2020, 2, 2063-2067.	0.6	2
263	Salt Taste Sensitivity and Heart Failure Outcomes Following Heart Failure Hospitalization. American Journal of Cardiology, 2020, 127, 58-63.	1.6	2
264	Cardiac amyloidosis in severe aortic stenosis: we can find it but what should we do?. European Journal of Heart Failure, 2020, 22, 1863-1865.	7.1	2
265	Disparities, Uncertainties, and Societal Cost: Precision Medicine and Transthyretin Amyloidosis. American Journal of Medicine, 2020, 133, 892-894.	1.5	2
266	Inclusion of Performance Parameters and Patient Context in the Clinical Practice Guidelines for Heart Failure. Journal of Cardiac Failure, 2021, 27, 190-197.	1.7	2
267	Relation between Modified Body Mass Index and Adverse Outcomes after Aortic Valve Implantation. American Journal of Cardiology, 2021, 153, 94-100.	1.6	2
268	Effects of Septal Reduction Therapy on Acute Cardiovascular Events and All-Cause Mortality in Patients with Hypertrophic Cardiomyopathy. International Heart Journal, 2021, 62, 1035-1041.	1.0	2
269	Relation of Body Mass Index to Transthyretin Cardiac Amyloidosis Particularly in Black and Hispanic Patients (from the SCAN-MP Study). American Journal of Cardiology, 2022, 177, 116-120.	1.6	2
270	The Wiggers Diagram: Hemodynamic Changes in Cardiac Amyloidosis. Journal of Cardiac Failure, 2023, 29, 217-219.	1.7	2

#	Article	IF	Citations
271	Top 10 List for the Cardiovascular Care of Older Adults. American Journal of Medicine, 2016, 129, 901-902.	1.5	1
272	Prognosis Using Planar Imaging in Cardiac Amyloidosisâ€"Reply. JAMA Cardiology, 2017, 2, 704.	6.1	1
273	Comparison of Effectiveness of Alcohol Septal Ablation Versus Ventricular Septal Myectomy on Acute Care Use for Cardiovascular Disease in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2019, 124, 1272-1278.	1.6	1
274	Days alive and outside of hospital from diagnosis of transthyretin vs. light chain cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 4-5.	3.0	1
275	Cardiac Amyloidosis. , 2020, , 301-310.e3.		1
276	Eosinophils, Lymphocytes, and Myocytes, Oh My: HIV-Associated Myocarditis. American Journal of Medicine, 2020, 133, 52-55.	1.5	1
277	Response by Kazi et al to Letter Regarding Article, â€œCost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathyâ€• Circulation, 2020, 142, e212-e213.	1.6	1
278	Cardiac Amyloidosis is Underdiagnosed in Patients Undergoing Transcatheter Aortic Valve Replacement. Structural Heart, 2020, 4, 512-514.	0.6	1
279	A Peak into the Pace of CardiacÂAmyloidosis. JACC: Clinical Electrophysiology, 2020, 6, 1155-1157.	3.2	1
280	Editorial for â€œReference Ranges, Diagnostic and Prognostic Utility of Native <scp>T1</scp> Mapping and Extracellular Volume for Cardiac Amyloidosis: A Metaâ€analysisâ€• Journal of Magnetic Resonance Imaging, 2021, 53, 1469-1470.	3.4	1
281	Response by Unlu et al to Letter Regarding Article, â€œPolypharmacy in Older Adults Hospitalized for Heart Failureâ€• Circulation: Heart Failure, 2021, 14, e008305.	3.9	1
282	Predictors of Survival in De Novo Cardiac Amyloidosis.. Blood, 2007, 110, 2870-2870.	1.4	1
283	A Proposal to Accelerate Widespread Implementation of Geriatric Cardiology. Trends in Cardiovascular Medicine, 2021, , .	4.9	1
284	Abstract 14398: African Americans With Transthyretin Cardiac Amyloidosis Have a Lower Prevalence of Atrial Fibrillation but Increased Thromboembolic Events Than Caucasians. Circulation, 2020, 142, .	1.6	1
285	Should Orthostatic Changes in Blood Pressure be Measured After One or Three Minutes in Elderly Subjects?. The American Journal of Geriatric Cardiology, 1998, 7, 29-33.	0.6	1
286	Impact of bone marrow minimal residual disease status on quality of organ response in systemic <scp>AL</scp> amyloidosis. American Journal of Hematology, 2022, 97, .	4.1	1
287	Society of Geriatric Cardiology. The American Journal of Geriatric Cardiology, 2006, 15, 319-321.	0.6	0
288	Society of Geriatric Cardiology. The American Journal of Geriatric Cardiology, 2006, 15, 398-398.	0.6	0

#	Article	IF	Citations
289	Society of Geriatric Cardiology. The American Journal of Geriatric Cardiology, 2006, 15, 263-267.	0.6	0
290	Society of geriatric cardiology. The American Journal of Geriatric Cardiology, 2006, 15, 194-196.	0.6	0
291	Society of Geriatric Cardiology. The American Journal of Geriatric Cardiology, 2007, 16, 205-208.	0.6	0
292	Society of Geriatric Cardiology. The American Journal of Geriatric Cardiology, 2007, 16, 54-55.	0.6	0
293	Paradoxical Low Flow/Low Gradient Severe Aortic Stenosis: an Emerging Phenotype in Older Adults with Valve Disease. Current Geriatrics Reports, 2015, 4, 353-361.	1.1	0
294	Use of Implantable Cardioverter-Defibrillators Among Medicare Patients. JAMA - Journal of the American Medical Association, 2015, 314, 1873.	7.4	0
295	Letter by Cohen and Maurer Regarding Article, â€œPrognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosisâ€. Circulation, 2016, 133, e449.	1.6	0
296	Call for New Therapies in HeartÂFailure. JACC: CardioOncology, 2019, 1, 305-306.	4.0	0
297	Transthyretin Stabilizer Is Associated With Expanding Apical Sparing Area and Improving Global Cardiac Function in a Patient With Wild-Type Cardiac Amyloidosis. Circulation Journal, 2019, 83, 690.	1.6	0
298	Norma: Participant 1,001 and the Value of Clinical Research. Journal of the American Geriatrics Society, 2020, 68, 2407-2408.	2.6	0
299	The association of prior carpal tunnel syndrome surgery with adverse cardiovascular outcomes and long-term mortality after aortic valve replacement. IJC Heart and Vasculature, 2021, 33, 100741.	1.1	0
300	The Potential Role of EHR data in optimizing eligibility criteria definition for cardiovascular outcome trials. International Journal of Medical Informatics, 2021, 156, 104587.	3.3	0
301	Can lightning strike twice? Wild-type transthyretin cardiac amyloidosis associated with rare liver disease. Oxford Medical Case Reports, 2021, 2021, omab113.	0.4	0
302	Impact of Light Chain Isotype on Clinical Features and Outcomes in Systemic AL Amyloidosis. Blood, 2021, 138, 4726-4726.	1.4	0
303	Abstract 15821: Patients With Amyloid Cardiomyopathy Who Receive Durable Mechanical Circulatory Support Are at Increased Risk for Mortality and Early Adverse Events. Circulation, 2020, 142, .	1.6	0
304	Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey. Blood, 2020, 136, 11-11.	1.4	0
305	Abstract 15242: Increased Mortality Among African American Patients With Heart Failure Caused by Hereditary Transthyretin Amyloid Cardiomyopathy. Circulation, 2020, 142, .	1.6	0
306	Amyloid Cardiomyopathy in Older Adults. Current Geriatrics Reports, 2022, 11, 1.	1.1	0

#	Article	IF	Citations
307	158â€ƒRacial differences in val122Ile associated transthyretin cardiac amyloidosis. European Heart Journal Supplements, 2021, 23, .	0.1	0
308	Impact of light chain isotype on clinical features and outcomes in systemic AL amyloidosis. Leukemia and Lymphoma, 2022, , 1-5.	1.3	0
309	Abstract 9735: Cost Effectiveness of Screening for Valvular Heart Disease Using the Valvenet Deep Learning Electrocardiogram Model. Circulation, 2021, 144, .	1.6	0